PMID- 37482500
OWN - NLM
STAT- MEDLINE
DCOM- 20231124
LR  - 20240410
IS  - 1938-0690 (Electronic)
IS  - 1525-7304 (Linking)
VI  - 24
IP  - 8
DP  - 2023 Dec
TI  - Efficacy of Tyrosine Kinase Inhibitors in Primary Driver-Gene-Positive Combined 
      Small-Cell Lung Cancer: A Retrospective Study.
PG  - 717-725.e1
LID - S1525-7304(23)00140-7 [pii]
LID - 10.1016/j.cllc.2023.07.001 [doi]
AB  - BACKGROUND: Combined small-cell lung cancer (c-SCLC) with gene mutations is a 
      rare subtype often found alongside adenocarcinoma. Targeted therapy may be 
      effective because of the presence of specific molecular targets. However, due to 
      its rarity and unconventional genetic testing, the efficacy remains uncertain. 
      METHODS: A total of 31 c-SCLC patients with gene mutations were retrospectively 
      included and grouped according to their treatment regimens. Treatment outcomes 
      were evaluated. Kaplan-Meier method was used for survival analysis, with Log Rank 
      test applied for comparison between groups. RESULTS: We divided the 31 patients 
      into 3 groups according to first-line treatment: group A (chemotherapy, n = 16), 
      group B (targeted monotherapy, n = 7), and group C (targeted combination therapy, 
      n = 8). The overall response rates (ORR) were 43.8%, 42.9%, and 62.5%. The 
      disease control rates (DCR) were 87.5%, 85.7%, and 100%. The median 
      progression-free survival (PFS) was 4.0, 5.0, and 7.93 months (P = .024), with a 
      significant difference between group A and C (P = .010). The median overall 
      survival (OS) was 14.10, 17.43, and 12.93 months (P = .313). Seven patients in 
      group A received targeted therapy in later-line. Of the total 22 patients 
      received targeted monotherapy or combination therapy, the ORR and DCR were 54.5% 
      and 90.9%. The median PFS and OS were 5.87 and 17.30 months. Additionally, 
      adverse events (AEs) occurred in 53.8% and 88.9% of monotherapy and combination 
      therapy. The most common AEs in monotherapy were elevated transaminases (23.1%) 
      and in combination anemia (66.7%). CONCLUSIONS: TKIs showed encouraging efficacy 
      in driver-gene-positive c-SCLC. While monotherapy may be a supplementary option, 
      combination with chemotherapy appears to be preferable and superior.
CI  - Copyright (c) 2023. Published by Elsevier Inc.
FAU - Shi, Zheng
AU  - Shi Z
AD  - Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou, China; Wenzhou 
      Medical University, Wenzhou, China.
FAU - Wei, Jingwen
AU  - Wei J
AD  - Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou, China; Wenzhou 
      Medical University, Wenzhou, China.
FAU - Sun, Wei
AU  - Sun W
AD  - Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou, China; Wenzhou 
      Medical University, Wenzhou, China.
FAU - Zeng, Xiaohong
AU  - Zeng X
AD  - Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou, China; Wenzhou 
      Medical University, Wenzhou, China.
FAU - Zhou, Huan
AU  - Zhou H
AD  - Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou, China; Zhejiang 
      Chinese Medical University, Hangzhou, China.
FAU - Song, Zhengbo
AU  - Song Z
AD  - Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou, China. 
      Electronic address: songzb@zjcc.org.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230705
PL  - United States
TA  - Clin Lung Cancer
JT  - Clinical lung cancer
JID - 100893225
RN  - 0 (Tyrosine Kinase Inhibitors)
SB  - IM
MH  - Humans
MH  - *Lung Neoplasms/drug therapy/genetics/pathology
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/pathology
MH  - Retrospective Studies
MH  - Tyrosine Kinase Inhibitors
MH  - *Small Cell Lung Carcinoma/drug therapy/genetics
OTO - NOTNLM
OT  - Adverse event
OT  - Clinical outcome
OT  - Gene mutation
OT  - Rare cancer
OT  - Targeted therapy
COIS- Disclosure All authors declare no conflict of interest.
EDAT- 2023/07/24 00:41
MHDA- 2023/11/24 06:42
CRDT- 2023/07/23 22:00
PHST- 2023/05/04 00:00 [received]
PHST- 2023/06/27 00:00 [revised]
PHST- 2023/07/02 00:00 [accepted]
PHST- 2023/11/24 06:42 [medline]
PHST- 2023/07/24 00:41 [pubmed]
PHST- 2023/07/23 22:00 [entrez]
AID - S1525-7304(23)00140-7 [pii]
AID - 10.1016/j.cllc.2023.07.001 [doi]
PST - ppublish
SO  - Clin Lung Cancer. 2023 Dec;24(8):717-725.e1. doi: 10.1016/j.cllc.2023.07.001. 
      Epub 2023 Jul 5.